Bifidobacterium animalis/cholecalciferol/lactobacillus rhamnosus gg Disease Interactions
There are 6 disease interactions with bifidobacterium animalis / cholecalciferol / lactobacillus rhamnosus gg.
- Arrhythmia
- Electrolyte imbalance
- Hypercalcemia
- Renal dysfunction
- Immunosuppression
- Hepatobiliary dysfunction
Vitamin D analogs (applies to bifidobacterium animalis/cholecalciferol/lactobacillus rhamnosus gg) arrhythmia
Major Potential Hazard, High plausibility. Applicable conditions: Arrhythmias
Vitamin D analogs function to increase serum calcium concentrations and can exacerbate arrhythmias, particularly in patients receiving cardiac glycosides. Therapy with vitamin D analogs should be administered cautiously in patients with or predisposed to cardiac arrhythmias. Clinical monitoring of serum electrolyte concentrations and cardiac function is recommended.
Vitamin D analogs (applies to bifidobacterium animalis/cholecalciferol/lactobacillus rhamnosus gg) electrolyte imbalance
Major Potential Hazard, High plausibility. Applicable conditions: Phosphate Imbalance
Vitamin D analogs administered in the presence of hyperphosphatemia can result in precipitation of calcium-phosphate deposits within the vascular or renal systems or other soft tissue calcifications. A solubility product (Serum Calcium X Phosphate) should not exceed 70. Serum electrolyte concentrations should be corrected prior to vitamin D analog therapy and monitored during therapy.
Vitamin D analogs (applies to bifidobacterium animalis/cholecalciferol/lactobacillus rhamnosus gg) hypercalcemia
Major Potential Hazard, Moderate plausibility. Applicable conditions: Malabsorption Syndrome
Vitamin D analogs such as calciferol and ergocalciferol should not be given to patients with hypercalcemia, malabsorption syndrome, or evidence of vitamin D toxicity.
Vitamin D analogs (applies to bifidobacterium animalis/cholecalciferol/lactobacillus rhamnosus gg) renal dysfunction
Major Potential Hazard, High plausibility.
Ergocalciferol, cholecalciferol, and calcifediol undergo renal biotransformation during metabolic activation. Renal impairment can alter metabolic and therapeutic activity of certain vitamin D analogs. Alternative vitamin D analogs such as dihydrotachysterol (hepatic activation) and calcitriol (active form) may be considered in patients with compromised renal function.
Probiotics (applies to bifidobacterium animalis/cholecalciferol/lactobacillus rhamnosus gg) immunosuppression
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Immunodeficiency, Immunodeficiency
Probiotics, especially those containing lactobacillus, should be used with caution in immunosuppressed patients.
Vitamin D analogs (applies to bifidobacterium animalis/cholecalciferol/lactobacillus rhamnosus gg) hepatobiliary dysfunction
Moderate Potential Hazard, High plausibility. Applicable conditions: Liver Disease, Biliary Obstruction
Vitamin D analogs are fat soluble and oral formulations require bile for adequate intestinal absorption. Hepatic and/or biliary dysfunction decrease the absorption of vitamin D analogs. Metabolites of vitamin D analogs are primarily excreted in bile and feces. Ergocalciferol, cholecalciferol, and dihydrotachysterol undergo hepatic hydroxylation during metabolic activation. Hepatic impairment can alter the metabolic and therapeutic activity of certain vitamin D analogs. Alternative vitamin D analogs such as calcifediol (requires renal activation) and calcitriol (active form) may be considered in patients with compromised hepatic function.
Bifidobacterium animalis/cholecalciferol/lactobacillus rhamnosus gg drug interactions
There are 422 drug interactions with bifidobacterium animalis / cholecalciferol / lactobacillus rhamnosus gg.
Bifidobacterium animalis/cholecalciferol/lactobacillus rhamnosus gg alcohol/food interactions
There is 1 alcohol/food interaction with bifidobacterium animalis / cholecalciferol / lactobacillus rhamnosus gg.
Report options
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.